Skip to main content

Table 3 Curative study

From: Evaluation of anti-malarial potency of new pyrazole-hydrazine coupled to Schiff base derivatives

Treatment Dose (mg/kg) Parasitaemia count
Day 0 Day 1 Day 2 Day 3
Control 6.76 ± 0.29 13.60 ± 0.62# 14.39 ± 0.27# 15.02 ± 0.53#
BePINH 2.5 7.70 ± 2.76 7.53 ± 2.49* 6.61 ± 1.63* 6.33 ± 2.80*
10 8.26 ± 2.40 6.56 ± 2.35* 5.58 ± 1.79* 5.04 ± 2.35*
15 6.63 ± 2.02 6.28 ± 1.85* 5.53 ± 1.63* 2.93 ± 1.73*
BePBeH 2.5 7.83 ± 2.58 7.79 ± 2.06 7.07 ± 1.65* 6.64 ± 2.45*
10 6.63 ± 2.10 6.77 ± 1.92* 6.56 ± 2.11* 5.31 ± 1.01*
15 6.35 ± 2.02 6.69 ± 1.77* 5.58 ± 1.55* 2.98 ± 0.57*
ACT 5 7.44 ± 2.01 6.66 ± 2.05* 3.03 ± 2.22* 1.40 ± 1.93*#
  1. Each value represents the mean ± S.E.M, n = 5
  2. ACT artemisinin-based Combination Therapy
  3. *,#p < 0.05 compared with control and Day 0, respectively (One-way ANOVA; Dunnett’s post hoc)